Most and least shorted mid- to mega-cap healthcare stocks at the end of August
Seeking Alpha News (Wed, 2-Sep 10:00 AM ET)
Bausch + Lomb Announces New Published Research on enVista Aspire Real World Experience
Business Wire (Wed, 2-Sep 7:00 AM ET)
Business Wire (Tue, 1-Sep 6:58 AM ET)
TipRanks (Fri, 28-Aug 6:25 AM ET)
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
Business Wire (Mon, 24-Aug 4:30 PM ET)
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
PRNewswire (Thu, 6-Aug 7:05 AM ET)
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance
Business Wire (Thu, 6-Aug 7:00 AM ET)
Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance
Business Wire (Wed, 29-Jul 6:58 AM ET)
Bausch + Lomb Launches EyeGility Inserter Preloaded IOL Delivery System in the United States
Business Wire (Thu, 16-Jul 7:00 AM ET)
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
Business Wire (Thu, 9-Jul 4:30 PM ET)
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Bausch & Lomb trades on the NYSE stock market under the symbol BLCO.
As of September 2, 2026, BLCO stock price climbed to $18.03 with 258,558 million shares trading.
BLCO has a beta of 0.78, meaning it tends to be less sensitive to market movements. BLCO has a correlation of 0.13 to the broad based SPY ETF.
BLCO has a market cap of $6.44 billion. This is considered a Mid Cap stock.
Last quarter Bausch & Lomb reported $1 billion in Revenue and $.16 earnings per share. This beat revenue expectation by $26 million and met earnings estimates .
In the last 3 years, BLCO traded as high as $21.69 and as low as $10.45.
The top ETF exchange traded funds that BLCO belongs to (by Net Assets): MGMT, DFAX, GVLU, DFIC, GUSA.
BLCO has outperformed the market in the last year with a price return of +23.2% while the SPY ETF gained +19.8%. BLCO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +17.2% and +5.8%, respectively, while the SPY returned +1.1% and -0.3%, respectively.
BLCO support price is $17.54 and resistance is $18.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLCO shares will trade within this expected range on the day.
